MedPath

Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis

Registration Number
NCT02183038
Lead Sponsor
Boehringer Ingelheim
Brief Summary

Study to assess the efficacy and tolerability of Meloxicam once daily dose of 7.5 mg and 15 mg compared with 1100 mg of naproxen sodium in the symptomatic treatment of acute non bacterial pharyngitis or pharyngo-tonsillitis, over a period of 5 days.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
390
Inclusion Criteria
  • Male or female aged 18 years or above

  • Ambulatory patients

  • Start of symptoms within the previous 24 hours

  • Patients suffering from acute non bacterial pharyngitis or pharyngo-tonsillitis diagnostic, under the following criteria:

    • spontaneous pharyngeal pain presence greater than 35 mm on a 100 mm visual analog scale (VAS)
    • Pharyngeal pain presence on swallowing greater than 35 mm on a 100 mm VAS
    • Pharyngeal and/or amygdaline hyperemia
    • Absence of purulent plaques
    • Negative test for β-haemolytic Streptococcus on pharyngeal exudate
  • Therapy with NSAID (Non-Steroid Anti-Inflammatory Drug) is required or recommended

  • Patient's informed consent in accordance with local law and ICH GCP (International Conference of Harmonization Good Clinical Practice) , before inclusion into the the trial

Read More
Exclusion Criteria
  • Suspicion of acute pharyngitis or pharyngo-tonsillitis from bacterial origin by clinical criteria; Several impairment of patients condition, indicated by one or more or the following symptoms:

    • Extremely rapid onset of clinical picture
    • Very high fever (>38.5°C)
    • Severe pharyngeal pain
    • Cervical adenopathy
    • Intense headache
    • Purulent pharyngeal plaques, evidence of peritonsillar abscess or phlegmon
  • Known or suspected hypersensitivity to the trial drug or NSAIDs

  • Positive test for β-haemolytic Streptococcus on pharyngeal exudate

  • Therapy with antimicrobial agents prior to start of the trial

  • Chronic infections

  • Infectious mononucleosis

  • Active peptic ulcer within the past 6 months

  • Pregnancy or breast feeding precaution: attention should be drawn to reports that NSAIDs were reported to decrease the efficacy of intrauterine devices

  • Asthma, nasal polyps, angioneurotic edema or urticaria following the administration of aspirin or NSAIDs

  • Concomitant treatment with anti-coagulants (including heparin), lithium or methotrexate

  • Concomitant administration of other NSAIDs (including high-dose > 1500 mg at day aspirin) or analgesic agents

  • Administration of any NSAID during the last three days or analgesics 6 hours prior to the first administration of the trial drug

  • Present treatment or treatment within the last two months with corticosteroids

  • Historically know of impaired renal function (serum urea > 125 % of the upper limit of normal range; serum creatinine > 150 % of the upper limit of normal range)

  • Historically know of severe liver injury (alanine amino transferase ALAT > 2 x the upper normal range limit or aspartate amino transferase ASAT > 2 x the upper normal range limit)

  • Historically know of hematological disorder (platelet count < 100,000/mm3, leucocyte count < 3,000/mm3)

  • Participation in another clinical trial during this study or during the previous month

  • Previous participation in this trial

  • Patient unable to comply with the protocol

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Meloxicam low & PlaceboNaproxen sodium placebo-
Meloxicam high & PlaceboNaproxen sodium placebo-
Meloxicam low & PlaceboMeloxicam low-
Meloxicam high & PlaceboMeloxicam high-
Meloxicam high & PlaceboMeloxicam placebo low-
Naproxen sodium & PlaceboMeloxicam placebo high-
Meloxicam low & PlaceboMeloxicam placebo high-
Naproxen sodium & PlaceboMeloxicam placebo low-
Naproxen sodium & PlaceboNaproxen sodium-
Primary Outcome Measures
NameTimeMethod
Change in intensity of spontaneous pharyngeal painBaseline, day 3 and 5
Change in intensity of pharyngeal pain on swallowingBaseline, day 3 and 5
Secondary Outcome Measures
NameTimeMethod
Final global assessment of tolerability by patientDay 5
Incidence of significant laboratory adverse eventsup to 19 days
Occurrence of pharyngeal hyperemiaup to 5 days
Number of patients who withdraw due to adverse eventup to 19 days
Number of patients with adverse eventsup to 19 days
Final global assessment of efficacy by patientDay 5
Final global assessment of efficacy by investigatorDay 5
Occurrence of disease systemic manifestations (fever, and general malaise)up to 5 days
Final global assessment of tolerability by investigatorDay 5
Assessment of patient statusDay 5
Occurrence of treatment withdrawal due to lack of efficacyup to 5 days
Intensity of adverse eventsup to 19 days
Occurrence and duration of hospital stay due to Gastro-Intestinal Serious Adverse Events (GI-SAE)up to 19 days
Occurrence and duration of hospital stay due to adverse events related to trial drug administrationup to 19 days
Occurrence of an additional visit at physician due to gastro-intestinal adverse event (GI-AE)up to 19 days
Occurrence of perforation, ulceration, bleeding (PUB) of the upper gastro-intestinal tract (stomach or duodenum)up to day 5
Number of patients with adverse events related to trial drugup to 19 days
© Copyright 2025. All Rights Reserved by MedPath